UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy

Aug.11.2022
UKVIA Expresses Disappointment Over Welsh Tobacco Control Strategy
The Welsh Tobacco Control Strategy lacks support for e-cigarettes and misses a significant opportunity for smoking cessation, says UKVIA.

The newly released Tobacco Control Strategy (TCS) in Wales has stated that it has not yet developed a position on e-cigarettes. The UKVIA has stated that, given the support of e-cigarettes in other parts of the UK, it will continue to engage with Welsh policymakers.


A plan to reduce smoking rates in Wales and achieve a "smoke-free" status by 2030 has been recently released. However, the plan has been criticized by the UK Vaping Industry Association (UKVIA) for lacking support for electronic cigarettes, which they describe as a missed opportunity. The UKVIA is the largest industry association representing the e-cigarette industry in the United Kingdom.


John Dunne, CEO of UKVIA stated, "While there are many commendable aspects to the strategy for reducing smoking rates in Wales, it is disappointing that the Welsh government hasn't gone further to seize this golden opportunity to embrace and advocate for e-cigarettes as the best and most effective way to help people quit smoking for good.


Although the Welsh TCS did mention e-cigarettes, it was only briefly noted that the Welsh government needs to develop its stance on e-cigarettes.


Dunne went on to say, "For this reason, we will continue to collaborate with the Welsh government, as in the recent example of the Khan review on smoking, which concluded that promoting e-cigarettes is absolutely crucial for achieving a smoke-free UK by 2030.


Welsh TCS has brought up the issue of preventing children and young people from smoking and using e-cigarettes - a topic that UKVIA has strongly advocated for. Dunne stated: "We welcome the Welsh government's plan to prevent young people from accessing e-cigarettes.


As an association, we have called on the UK government to impose stricter regulations on e-cigarette retailers who sell to young people. We recommend a fine of £10,000 for those caught in violation.


Returning to Wales, TCS lacks support for e-cigarettes as a tool to quit smoking. Dunne added, "There is indisputable evidence that e-cigarettes are effective in helping adults quit smoking. Support is growing among the scientific, academic, healthcare, and political communities, all of which now recognize e-cigarettes as an important component in helping smokers quit.


While it is disappointing to see that the Welsh government has not taken a more proactive stance on e-cigarettes, it is important to engage with politicians and decision-makers in the region to showcase the value of these devices and help the country achieve its smoke-free goals. Failing to do so could have serious consequences for Wales' ability to reduce smoking rates and minimize harm.


Meanwhile, in Scotland, a survey of 2,170 individuals found that 41% of respondents reported that e-cigarettes helped them quit smoking. The survey also found that only one-sixth of respondents wished for stricter regulations on e-cigarettes, while half hoped for more relaxed regulations. Scotland's government is currently considering whether to ban in-store promotions of e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry professionals for educational and informational purposes only.


This article does not necessarily represent the views of 2FIRSTS, and 2FIRSTS cannot verify the truth or accuracy of the article's content. The translation of this article is intended only for internal industry discussion and research purposes.


Due to limitations in translation skills, the translated article may not accurately convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regard to any domestic, Hong Kong, Macao, Taiwan, or foreign statements and positions.


All compiled information is owned by the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea's Constitutional Court has upheld fixed taxes on nicotine-containing e-cigarette liquids based on solution volume, ruling that challenged provisions imposing KRW 370 per milliliter in individual consumption tax and KRW 628 per milliliter in tobacco consumption tax do not violate the Constitution. The cases stemmed from historical disputes involving importers that reported nicotine as being extracted from tobacco stems rather than leaves. South Korea has since broadened its tobacco definition to include synthetic nicotine, while current tax laws provide reduced rates for certain products not derived from tobacco.
Sep.18
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07